Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR-002 in Advanced Treatment-Refractory Solid Tumors
NCT07189195Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Nov 2025
- Primary completion
- Nov 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nadofaragene firadenovec in solid tumor and pancreatic adenocarcinoma (PDAC), sponsored by University of California, Davis. Primary endpoints: Incidence of dose limiting toxicity at Day 28 and Number of participants experiencing treatment-related adverse events. Started Nov 2025; status: recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07189195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189195.